StockNews.com Upgrades ANI Pharmaceuticals (NASDAQ:ANIP) to Hold

ANI Pharmaceuticals (NASDAQ:ANIP) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Friday.

Other research analysts have also recently issued research reports about the company. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. JPMorgan Chase & Co. assumed coverage on ANI Pharmaceuticals in a research report on Wednesday. They issued an “overweight” rating and a $85.00 price target for the company. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research report on Friday. They issued a “buy” rating and a $80.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, March 3rd. Finally, Leerink Partners assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, ANI Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $79.75.

ANI Pharmaceuticals Trading Up 1.7 %

Shares of ANIP stock opened at $62.49 on Friday. ANI Pharmaceuticals has a fifty-two week low of $52.50 and a fifty-two week high of $70.81. The stock has a market cap of $1.36 billion, a P/E ratio of -113.62 and a beta of 0.62. The business has a fifty day simple moving average of $58.40 and a 200-day simple moving average of $58.09. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

Insiders Place Their Bets

In other news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $60.20, for a total value of $60,200.00. Following the transaction, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at $4,131,164.80. The trade was a 1.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the transaction, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 10,700 shares of company stock valued at $610,201. Insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC lifted its stake in shares of ANI Pharmaceuticals by 89.3% in the 4th quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company’s stock valued at $55,437,000 after purchasing an additional 473,097 shares in the last quarter. State Street Corp raised its holdings in shares of ANI Pharmaceuticals by 9.1% during the 3rd quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company’s stock valued at $41,991,000 after buying an additional 58,698 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of ANI Pharmaceuticals by 4.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company’s stock valued at $37,906,000 after buying an additional 30,420 shares during the period. Deep Track Capital LP raised its holdings in shares of ANI Pharmaceuticals by 28.6% during the 4th quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company’s stock valued at $35,879,000 after buying an additional 144,214 shares during the period. Finally, Global Alpha Capital Management Ltd. raised its holdings in shares of ANI Pharmaceuticals by 16.4% during the 4th quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company’s stock valued at $34,525,000 after buying an additional 88,100 shares during the period. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.